Aragen Life Sciences Sustainability Profile
Aragen Life Sciences, a prominent player in the biotechnology sector, is headquartered in India and operates extensively across major regions, including North America and Europe. Founded in 2000, the company has established itself as a leader in providing integrated solutions for drug discovery, development, and manufacturing. Aragen's core offerings encompass a wide range of services, including biologics, small molecules, and custom research, distinguished by their commitment to innovation and quality. The company has achieved significant milestones, such as expanding its capabilities in biologics and securing partnerships with leading pharmaceutical firms. With a strong market position, Aragen Life Sciences is recognised for its expertise and reliability, making it a preferred partner for clients seeking comprehensive life science solutions.
DitchCarbon Score
How does Aragen Life Sciences's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aragen Life Sciences's score of 92 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aragen Life Sciences's reported carbon emissions
In 2024, Aragen Life Sciences reported total greenhouse gas emissions of approximately 60,000 tonnes CO2e for Scope 1, 34,544 tonnes CO2e for Scope 2, and 40,817 tonnes CO2e for Scope 3. This data reflects a comprehensive approach to emissions reporting, covering all three scopes. Notably, the company aims to reduce its absolute Scope 1 and 2 emissions by 50.4% by FY2033, using FY2023 as the base year. Additionally, Aragen has set a long-term target to achieve net-zero emissions across all scopes by 2050. In 2023, emissions were recorded at approximately 9,544 tonnes CO2e for Scope 1, 37,600 tonnes CO2e for Scope 2, and 55,072 tonnes CO2e for Scope 3. The company has committed to significant reductions, including a 20% decrease in emissions intensity for both Scope 1 and 2 by 2025 compared to 2021 levels. Aragen's climate commitments align with the Government of India's targets under the Paris Agreement, aiming for net-zero GHG emissions by 2070. The company is actively working towards these goals, demonstrating a robust commitment to sustainability within the pharmaceuticals and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 10,268,000 | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 25,554,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 00,000,000 | 00,000,000 |
How Carbon Intensive is Aragen Life Sciences's Industry?
How Carbon Intensive is Aragen Life Sciences's Location?
Aragen Life Sciences's Scope 3 Categories Breakdown
Aragen Life Sciences's Scope 3 emissions, which decreased by 26% last year and decreased by approximately 26% since 2023, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 50% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 56% of Scope 3 emissions.
Top Scope 3 Categories
Aragen Life Sciences's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aragen Life Sciences has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Anthem Biosciences
Frequently Asked Questions
Common questions about Aragen Life Sciences's sustainability data and climate commitments